Our research focuses on lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammation-related biomarker that has recently garnered interest in the context of NASH due to its potential roles in disease pathogenesis and progression. This evidence concerns the gene PLA2G7 and metabolic dysfunction-associated steatohepatitis.